NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
R. Somwar, N. Hofmann, Bryan D. Smith, I. Odintsov, M. Vojnic, I. Linkov, Ashley Tam, I. Khodos, M. Mattar, E. de Stanchina, D. Flynn, M. Ladanyi, A. Drilon, U. Shinde, M. Davare
Communications Biology